Company research
Pulsenmore Ltd.
CIK 2064764Updated Nov 6, 2026
SecurityPLSM · NASDAQ · equity
PLSM price & chart
Loading TradingView…
NASDAQ:PLSM on TradingView ↗In the news
Pulsenmore Announces Pricing of $7.5 Million Private Placement with a Single Healthcare Focused Institutional Investor ↗
Pulsenmore To Commence Trading on Nasdaq as It Expands FDA-authorized Home Prenatal Ultrasound Devices in the U.S. News provided by Pulsenmore Ltd. Jan 21, 2026, 07:30 ET Share this article Share to X Share this article Share to X RAMAT GAN, Israel , Jan. 21, 2026 /PRNewswire/ -- Pulsenmore Ltd. ( ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
cash flow · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cash flows from operating activities: | ||
| Profit or LossUSD | -4,970,000Source | -36,736,000Source |
| Additional Financial Items | ||
| AdjustmentsForDecreaseIncreaseInTradeAccountReceivableUSD | -74,000Source | -2,947,000Source |
| AdjustmentsForSharebasedPaymentsUSD | 209,000Source | 1,388,000Source |
| GeneralAndAdministrativeExpenseUSD | 5,230,000Source | 15,344,000Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 369,000Source | 1,167,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 |
|---|---|---|
| Cost of Goods and Services Sold | —Source | —Source |
| Total RevenueUSD | 12,547,000Source | 9,661,000Source |
| Additional Financial Items | ||
| BasicEarningsLossPerShareUSD per share | 0.77Source | 5.76Source |
| DepreciationAndAmortisationExpenseUSD | 879,000Source | 2,852,000Source |
| DepreciationRightofuseAssetsUSD | 303,000Source | 1,011,000Source |
| DilutedEarningsLossPerShareUSD per share | 0.77Source | 5.76Source |
| EmployeeBenefitsExpenseUSD | 414,000Source | 1,334,000Source |
| FinanceIncomeUSD | 1,109,000Source | 5,963,000Source |
| GeneralAndAdministrativeExpenseUSD | 5,230,000Source | 15,344,000Source |
| GrossProfitUSD | 10,559,000Source | 3,577,000Source |
| IncomeTaxExpenseContinuingOperationsILS | 1,000Source | -56,000Source |
| InterestExpenseUSD | 2,265,000Source | 540,000Source |
| InterestExpenseOnLeaseLiabilitiesUSD | 99,000Source | 492,000Source |
| NetForeignExchangeLossUSD | 879,000Source | — |
| ProfitLossBeforeTaxUSD | -4,970,000Source | -36,792,000Source |
| ResearchAndDevelopmentExpenseUSD | 5,439,000Source | 20,130,000Source |
Offerings
Registration 333-297237
Filing attachments
ex99-1.htm · 6-K · 2026-10-13
Exhibit 99.1 Pulsenmore Strengthens U.S. Commercial Leadership, Appoints Med-Tech Veteran David Woods as Chief Commercial Officer Expanded commercial team to accelerate U.S. growth as demand for accessible prenatal care and federal rural health investments create new opportunities Ramat Gan, Israel, October 13, 2026 - Pulsenmore Ltd. (Nasdaq/TASE: PLSM) (“Pulsenmore” or the “Company”), a pioneer in patient-operated home ultrasound technology, today announced the appointment of David Woods as …
Read attachment ↗ex99-1.htm · 6-K · 2026-09-17
Exhibit 99.1 Pulsenmore Expands Its Fertility Platform into the UK MHRA registration allows Pulsenmore FC to be marketed across the United Kingdom and Northern Ireland, extending the Company’s home ultrasound platform into the UK fertility market where more than 100,000 IVF and fertility treatment cycles were performed in 2024. OMER, Israel, September 17, 2026 - Pulsenmore (Nasdaq/TASE: PLSM), a healthcare technology company developing self-use ultrasound solutions for remote care, today anno…
Read attachment ↗ex99-1.htm · 6-K · 2026-09-08
Exhibit 99.1 Pulsenmore Expands into Fertility Care: Completes CE European Registration of Home Ultrasound System for Follicular Monitoring The Pulsenmore FC system is designed to enable women undergoing IVF and fertility preservation treatments to self-perform ultrasound scans from home. This registration marks the Company’s second product authorized in Europe and its first expansion beyond prenatal care into the broader women’s health market. OMER, Israel, September 8, 2026 - Pulsenmore Lt…
Read attachment ↗ex107.htm · S-8 · 2026-08-31
Calculation of Filing Fee Tables S-8 Pulsenmore Ltd. ──────────────────────────────────── Table 1: Newly Registered Securities ──────────────────────────────────────── Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum …
Read attachment ↗ex99-1.htm · 6-K · 2026-08-31
Exhibit 99.1 PULSENMORE LTD. CONDENSED CONSOLIDATED INTERIM STATEMENTS (UNAUDITED) AS OF JUNE 30, 2026 PULSENMORE LTD. CONDENSED CONSOLIDATED INTERIM STATEMENTS (UNAUDITED) AS OF JUNE 30, 2026 TABLE OF CONTENTS Page Condensed consolidated interim statements of financial position F-1 Condensed consolidated interim statements of comprehensive loss F-2 Condensed consolidated interim statements of cha…
Read attachment ↗ex99-2.htm · 6-K · 2026-08-31
Exhibit 99.2 OPERATING AND FINANCIAL REVIEW The following discussion and analysis of our operating and financial condition and prospects provides information that we believe to be relevant to an assessment and understanding of our operating and financial condition for the periods described. You should read the following discussion of our operating and financial condition and prospects in conjunction with the financial statements and the notes thereto included elsewhere in this 6-K, as well as …
Read attachment ↗